After AstraZeneca and Daiichi Sankyo made waves in June with eye-opening results for Enhertu in a combination treatment for a ...
The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...
Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...
A new survey from SiriusXM Media details the issues that many people have with the current state of TV drug ads—and ...
LIB Therapeutics has scored an FDA approval for its cholesterol-lowering, third-generation PCSK9 inhibitor, lerodalcibep-liga ...
While argenx has been able to demonstrate the merit of its FcRn drug Vyvgart in multiple autoimmune indications, not every ...
After a three-decade drought of new antibiotics to treat gonorrhea, the FDA has signed off on two first-in-class oral ...
Eli Lilly will not seek a broad FDA approval for a combination of the company’s oral SERD med Inluriyo and CDK4/6 inhibitor ...
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
New CDC report backs COVID vaccine effectiveness in children as vaccine safety probe heats up at FDA
As regulatory uncertainty around COVID vaccines continues to swirl, a new report from the Centers for Disease Control and Prevention (CDC) showcases the benefits of the immunizations among children | ...
As it shifts strategic direction to prioritize its recently acquired ENvue feeding tube placement system, NanoVibronix is changing its name to reflect the new focus. | As it shifts strategic direction ...
Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback